Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Escitalopram - Lundbeck A/S

Next Previous
Drug Profile

Escitalopram - Lundbeck A/S

Alternative Names: Cipralex; Entact; Escitalopram Oxalate; Lexapro; LU-26054; MLD-55; S-citalopram; Seroplex; Sipralex; Sipralexa

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lundbeck A/S
  • Developer AbbVie; Forest Laboratories; Lundbeck A/S; Mochida Pharmaceutical
  • Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Benzofurans; Fluorobenzenes; Nitriles; Propylamines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Social phobia

Most Recent Events

  • 22 Nov 2022 Escitalopram is still in phase-III trials for Major depressive disorder (In adolescents, In children) in Japan (PO) (Mochida Pharmaceutical pipeline, November 2022)
  • 08 Mar 2022 No development reported - Phase-III for Major depressive disorder (In adolescents, In children) in Japan (PO)
  • 08 May 2020 Allergan has been acquired and merged into AbbVie

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top